| Literature DB >> 32238909 |
Norman Delanty1,2,3, Gianpiero L Cavalleri4,5, Katherine A Benson1,2, Maire White1, Nicholas M Allen6, Susan Byrne1,2,7, Robert Carton1,2, Elizabeth Comerford1, Daniel Costello8, Colin Doherty9, Brendan Dunleavey10, Hany El-Naggar1,2,3, Nisha Gangadharan1,2, Sinéad Heavin1, Hugh Kearney1,2,3, Nicholas J Lench11, John Lynch12, Mark McCormack1, Mary O' Regan7, Karl Podesta13, Kevin Power1,2, Anthony S Rogers11, Charles A Steward11, Brian Sweeney8, David Webb7, Mary Fitzsimons1,2, Marie Greally1.
Abstract
Next generation sequencing provides an important opportunity for improved diagnosis in epilepsy. To date, the majority of diagnostic genetic testing is conducted in the paediatric arena, while the utility of such testing is less well understood in adults with epilepsy. We conducted whole exome sequencing (WES) and copy number variant analyses in an Irish cohort of 101 people with epilepsy and co-morbid intellectual disability to compare the diagnostic yield of genomic testing between adult and paediatric patients. Variant interpretation followed American College of Medical Genetics and Genomics (ACMG) guidelines. We demonstrate that WES, in combination with array-comparative genomic hybridisation, provides a diagnostic rate of 27% in unrelated adult epilepsy patients and 42% in unrelated paediatric patients. We observe a 2.7% rate of ACMG-defined incidental findings. Our findings indicate that WES has similar utility in both adult and paediatric cohorts and is appropriate for diagnostic testing in both epilepsy patient groups.Entities:
Mesh:
Year: 2020 PMID: 32238909 PMCID: PMC7381648 DOI: 10.1038/s41431-020-0610-3
Source DB: PubMed Journal: Eur J Hum Genet ISSN: 1018-4813 Impact factor: 4.246